General MedicationsINJECTIONStandard
ENSPRYNG
SATRALIZUMAB
Standard Dose
120MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ENSPRYNG is listed in Drugs@FDA under application 761149 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient SATRALIZUMAB Form and strength INJECTABLE;INJECTION - 120MG/ML Sponsor GENENTECH Submission history Latest submission status date: 2022-09-14 00:00:00.
Structured Monograph
Clinical summary
Approval overview ENSPRYNG is listed in Drugs@FDA under application 761149 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient SATRALIZUMAB Form and strength INJECTABLE;INJECTION - 120MG/ML Sponsor GENENTECH Submission history Latest submission status date: 2022-09-14 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.